

NextCell invited presenter at International Society for Cell and Gene Therapy meeting in Paris

NextCell Pharma AB's ("NextCell" or the "Company") CSO, Dr Lindsay Davies, has been invited to give a poster presentation at the ISCT meeting in Paris, showcasing NextCell's long-term follow-up data from their phase II type I diabetes study with investigative medicinal product, ProTrans.

Dr Davies has been invited to present a poster at the ISCT meeting, entitled, "A single infusion of ProTrans mesenchymal stromal cell product maintains endogenous insulin production in type 1 diabetes patients – a long term follow-up study."

This year's ISCT meeting will focus on "celebrating the progress of advanced therapies and building the future through translations". The meeting will be held at Palais des Congres de Paris, Paris, France, from Wednesday 31st of May to Saturday 3rd of June and will cover topics spanning translational and preclinical development through to clinical trials, regulatory approvals, commercialization and patient access.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel: 08-735 5595

E-mail: info@nextcellpharma.com

Website: www.nextcellpharma.com

LinkedIn: <https://www.linkedin.com/company/15255207/>

Twitter: <https://twitter.com/NextCellPharma>

About NextCell Pharma AB

NextCell is a cell therapy company in clinical phase II. The company has developed a proprietary and patented platform technology to produce mesenchymal stromal cells adapted for allogeneic treatment of various autoimmune and immunological diseases. The drug candidate ProTrans is now being tested for the treatment of type-1 diabetes as well as respiratory complications caused by Sars-CoV-2 infection. The focus is to take ProTrans to market approval for type-1 diabetes via a phase III study. ProTrans is evaluated in two clinical COVID-19 studies, in Sweden and Canada. NextCell is working on completing its own GMP facility for the manufacture of ProTrans. The GMP facility is expected to be ready for manufacturing smaller quantities of ProTrans in 2023. NextCell also owns 8.5% of FamicordTX, a start-up company in CAR-T and oncology, and 100% of Cellaviva, Scandinavia's largest stem cell bank for family savings of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).